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[57] ABSTRACT
The present invention involves the synthesis and use of
new platinum compounds. These new platinum com-
pounds are easy to encapsulate in liposomes at high
efficiencies. They are further characterized as platinum





wherein R; and R2 are carboxylato monoanionsbearing
a hydrophobic radical function or a single carboxylato
dianion bearing a hydrophobic radical function and R3
is a vicinal diaminoalkane or vicinal diaminocycloal-
kane. The complex is substantially soluble in methanol
or chloroform and substantially insoluble in water. Said
complex may be incorporated into phospholipid lipo-
somes. Such platinum complexes encapsulated in phos-
pholipid liposomesare useful for chemotherapyofplati-
num complex-sensitive tumors. :






This patent application is a divisional of U.S. patent
application Ser. No. 914,591, filed on Oct. 7, 1986, now
U.S. Pat. No. 5,041,581 which was a continuation-in-
part of U.S. patent application Ser. No. 788,750, filed on
Oct. 18, 1985, now abandoned.
BACKGROUND OF THE INVENTION
This invention relates to newly synthesized platinum
complexes with hydrophobic properties. The use of
liposomes incorporating these new and previously syn-
thesized complexes in anti-tumor chemotherapy is also
described.
Cis-platinum (CDDP)is a highly effective drug in the
treatment of several neoplastic diseases in humans (Lo-
ehrer et al (1984) Ann. Int. Med. V 100, pp 704-713).
However,its use is limited by severe systemic toxicity,
particularly nephrotoxicity and neurotoxicity (Zwelling
et al Platinum Complexes. In: Pharmacologic principles
of cancer treatment (1982) Ed by B. A. Chabner, Saun-
ders, Philadelphia, Pa.). In an attempt to modify the
therapeutic index of CDDP, new derivatives have been
synthesized during the last decade. However,the devel-
opment of some promising analogues has been pre-
vented by their low hydrosolubility, which decreases
their potential for clinical use (Burchenal et al (1979)
Cancer Treat. Rep. V 63, pp 1493-1497).
Liposomesarelipid vesicles which may form sponta-
neously upon addition of an aqueoussolution to a dry
lipid film (Mayhewet al, In: Liposomes (1983) Ed by
MarcJ. Ostro, Marcel Dekker, Inc., New York, N.Y.).
Liposomes maybe used as drug carriers of hydrophobic
or hydrophilic drugs entrapped in their hydrophobic or
hydrophilic compartments respectively. Multilamellar
liposomes are multilayer lipid vesicles (MLV) that are
particularly suited for carrying hydrophobic drugs
since their hydrophobic compartment is larger than
their hydrophilic compartment. When injected intrave-
nously (iv) in animals, (Kasi et al (1984) Int. J. Nucl.
Med. Biol. V 11 pp 35-37, Lopez-Berestein et al.
(1)(1984) Cancer Drug Deliv. V 1, pp 199-205) and
humans(Lopez-Berestein etal (2)(1984), Cancer Res. V
44, pp 375-378), MLV concentrate in the liver, spleen
and other organsrich in reticuloendothelial (RES)cells.
Liposomes have been previously used in vitro to
deliver chemotherapeutic agents, (Mayhewet al, Lipo-
somes (1983), Ed by Ostro, Marcel Dekker, Inc., New
York, N.Y.) and immunomodulators and anti-fungal
agents in vitro (Mehta et al (1984), Immunology V 51
pp 517-527, and in vivo in animals (Lopez-Berestein et
al (4)(1984) Clin Exp Metastasis V 2 pp 127-137 and
Lopez-Berestein et al (1983), J Inf Dis V 147, pp
937-945) and in humans (Lopez-Berestein et al (1985)J.
Inf. Dis. V 151 pp 704-710).
Recent studies show that liposomes can reduce cer-
tain types of drug-related toxicities such as doxorubicin
cardiotoxicity (Forssen et al (1981) Proc. Natl. Acad.
Sci. V 78 pp 1873-1877, Olson et al (1982), Eur. J. Can-
cer Clin. Oncol. V 18 pp 167-176, Gabizon et al (1982)
Cancer Res. V 42 pp 4734-4739, Hermanet al (1983)
Cancer Res. V 43 pp 5427-5432) and CDDP nephrotox-
icity, (Freise et al (1982), Arch. Int. Pharmacodynamie
Therapie V 258 pp 180-192) and mayincrease antitu-











(Mayhewet al (1978) Ann. N.Y. Acad. Sci. V 308, pp
371-386, - Patel et al (1984) Int. J. Cancer V 34 pp
717-723) a higher drug uptake by tumorcells or due to
amoreselective organ distribution (Gabizonetal (1983)
Cancer Res. V 43, pp 4730-4735 and Mayhew et al
(1983), Cancer Drug Deliv. V 1 pp 43-58). In U.S. Pat.
No.4,330,534 N4-acylcytosine arabinoside incorporated
into liposomes, for example, was found to be therapeuti-
cally effective when administered to tumor-bearing
animals. In spite of these promising results, the clinical
application of antitumor agents encapsulated in lipo-
somes has been delayed, mainly due to formulation,
drug stability and large scale production problems.
CDDPhas been previously encapsulated in MLV but
with a very low encapsulation efficiency (7.4%) and
poorstability (75% at 48 hours in 0.9% NaClsolution)
(Freise et al (1982) Arch. Int. Pharmacodynamie Thera-
pie V 258 pp 180-192).
In U.S. Pat. No. 4,256,652 are described certain plati-
num compounds comprising resolved stereoisomers of
1,2 diaminocyclohexane (DACH). Theisomersutilized
were cis-DACH, trans-RR-DACH and _trans-SS-
DACH. The platinum compounds described therein
contained,in addition to a resolved DACHisomer, two
hydrophilic platinum ligands such as bromide, iodide,
nitrate, bromoacetate, sulfate or glucuronate. Theplati-
num compounds comprising the trans-RR-DACH were
described as often more therapeutically effective than
those bearing cis-DACH.
In European Patent Application No. 83306726.7 cer-
tain platinum compounds are described which may
comprise diaminocyclohexane (non-stereochemically
resolved) and do comprise phosphatidy! groups having
fatty acid substituents. These compoundsare described
as largely insoluble in plasma and preferably employed
with lipid vesicle carriers. The platinum compound-
Phospholipid vesicles were preferably prepared by a
sonic oscillation procedure which characteristically
yields unilamellar vesicles.
SUMMARYOF THE INVENTION
The presentinvention comprises a platinum (IT) four-





In this formula Rj and R2 are each carboxylates bearing
a hydrophobic radical function, most preferably neode-
cyl, or, when linked together, are a dicarboxylato bear-




In this latter formula, Rs is selected from the group
consisting of hydrogen, an alkyl having from 2 to 6
carbon atomssuch as isopropyl, aryl, aralkyl, alkenyl, a
cycloalkyl such as cyclohexyl, cycloalkenyl and a com-
bination thereof. Rs is preferably hydrogen, alkyl hav-
ing between 1 and 20 carbon atoms, more preferably
between 6 and 12 carbon atoms and most preferably
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between 2 and 6 carbon atoms or cycloalkyl having
between 3 and 12 carbon atoms.
Additionally R3 and R4 may be linked together in a
single function. When R3 and Rg, are so linked together,
they are preferably selected from the group consisting 5
of cycloalkyl-1,2-diamino functions having between
about 3 and 7 carbon atoms, and alkyl-1,2-diamino hav-
ing between about 2 and 12 carbon atoms, preferably
ethyl. A preferred cycloalkyl-1,2-diamino componentis
1,2-diaminocyclohexane, preferably in the trans-R,R- or 10
trans-S,S- form.
In the above-described complex the carboxylato of
Ry and R2 is preferably an alkylcarboxylato having
between about 5 and 20 carbon atoms, an arylcarbox-
ylato wherein aryl is phenyl, naphthyl, or an alkyl- 15
phenyl wherein the alkyl phenyl has between about 12
and 16 carbon atoms.
When the complex contains R; and R2 as a dicarbox-
ylato, the dicarboxylato is preferably an alkyldicarbox-
ylato having between about 5 and 20 carbon atoms, or
an aryldicarboxylato wherein aryl is naphthyl, phenyl,
or alkylpheny! wherein the alkyl of the alkylphenyl has
between about 6 and 12 carbon atoms. Asused in the
above description the term aryl is defined further as a
function preferably having between about 6 and 14
carbon atoms. Likewise the term alkenylis preferably a
function having between about 5 and 20 carbon atoms.
The cycloalkyl!referred to in the present descriptions
is preferably a function having between about 3 and 12
carbon atoms. The cycloalkenyl term as used aboveis
preferably a function having between about 5 and 20
carbon atoms. The term aralkyl as used aboveis a func-
tion preferably having between about 7 and 20 carbon
atomsand contains linked ary] and alkyl portions. The
aryl portion herein preferably has between about 6 and
10 carbon atoms and the alkyl portion preferably has
between about | and 10 carbon atoms. When R3 and R4
are taken together they are preferably a cycloalkyl-1,2-
diamino having between about 3 and 20 carbon atoms.
The alkyl ring of the cycloalkyl preferably has between
about 3 and 12 carbon atoms.
A further aspect of the present invention concerning






concerns the case where Rand R2, taken together, are











where Rgis alkyl! having between about 10 and 20 car-
bon atoms, preferably pentyl, neopentyl, decyl or 65
neodecyl and R7and Rg are each hydrogenor an alkyl
having between about 1 and 5 carbon atoms.
As described above R3 and Rg are each:
25
When R3 and Rygare taken together they are selected
from the group consisting of cycloalkyl-1;2-diamino
having between about 3 and 7 carbon atoms, and alky]-
1,2-diamino having between about 2 and 12 carbon
atoms. The cycloalkyl-1,2-diamino is preferably 1,2-
diaminocyclohexane and more preferably trans-R,R-
1,2-diaminocyclohexane or trans-S,S-1,2-diaminocy-
clohexane. This complexis, as described above, substan-
tially soluble in methano! or chloroform and substan-
tially insoluble in water.
Important aspects of the present invention involve
liposomes comprising fatty substances such as phospho-
lipids, optionally cholesterol, and the four-coordinate
platinum complexes described above, as well as the
preparation and uses of these liposomes. Liposomes of
the present invention contain the platinum complex and
the phospholipid in a preferred ratio between about | to
10 and about1 to 30, a more preferred ratio being 1 to
15.
' Preferred phospholipids of these liposomes include
phosphatidylglycerol, phosphatidylcholine, sphingo-
myelin, phosphatidic acid or phosphatidylserine, the
more preferred phospholipids being phosphatidyl-
glycerol, phosphatidylcholine or a combination thereof.
The mostpreferred phosphatidylglycerol is one consist-
ing essentially of dimyristoylphosphatidylglycerol and
the most preferred phosphatidylcholine is one consist-
ing essentially of dimyristoylphosphatidylcholine.
Whenthe liposomes of the present invention comprise
dimyristoylphosphatidylglycerol and dimyristoylphos-
phatidylcholine they are preferably in a ratio between
about 1-10 and 10-1, more preferably in a ratio of about
3 to 7.
The liposomes of the present invention may be mul-
tilamellar, unilamellar or have an undefined lamellar
construction. A pharmaceutical composition compris-
ing the liposomes of and a pharmaceutically acceptable
carrier or diluent may be used for the therapy of disease
conditions such as cancer.
A focal point of the present invention involves a
methodof treating a host animal afflicted with tumor
cells sensitive to the presence of a platinum (I) four-
coordinate complex. This method comprises adminis-
tering to the host an amountofthe platinum (II) four-
coordinate complex described above or a liposome of
the present invention comprising a phospholipid and a
tumorcell-inhibiting effective amount of said platinum
complex. The administering step is preferably paren-
teral and by intravenous, intraarterial, intramuscular,
intralymphatic, intraperitoneal, subcutaneous, intra-
pleural or intrathecal injection or by topical application
or oral dosage. Such administration is preferably re-
peated on a timed schedule, for example twice daily for
a period of two weeks. The treatment may be main-
tained until tumor regression or disappearance has been
achieved and may be used in conjunction with other
forms of tumor therapy such as surgery or chemother-
apy with different agents.
These antitumor methods mayalso be used to inhibit
the metastatic spread of tumors such as reticulosar-
coma. A preventative pretreatment with the platinum-
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(II) complexes or liposomes comprising those com-
plexes may be used to preclude metastatic spread in a
vaccination-like manner.
DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
Platinum (II) four-coordinate complexes were pre-
pared utilizing racemic (unresolved) DACH,trans-RR-
DACHortrans-SS-DACH.It was found that platinum
complexes comprising trans-RR-DACH or trans-SS-
DACHandtwo hydrophobic ligands such as cyclopen-
tene-carboxylato were more efficiently incorporated
into liposomes than were the analogous complexes com-
prising racemic DACH.
Liposomes incorporating these platinum complexes
were found to be stable in an aqueous milieu, non-
nephrotoxic and active against murine leukemia L-1210.
In a general sense, the square-planar platinum (IJ)






where R, and R2 are preferably carboxylato monoan-
ions bearing a hydrophobic radical function. Rj and R2
may also be a single carboxylato dianion where the
carboxylato groups are boundto an interlinking atom
which in turn is bound to a radical function. Addition-
ally, R3 is a vicinal diaminoalkane or vicinal diaminocy-
cloalkane. It is contemplated that R3 may be composed
of two independent alkylamines, cycloalkylamines or
ammonia. These components confer upon the complex
a substantial solubility (normally greater than about 5.0
mg/ml) in methanol or chloroform at ambient tempera-
tures and a substantial insolubility (less than about 0.5
mg/ml) in aqueous solutions at ambient temperatures.
The hydrophobic radical function, that function co-
valently pendant from the carboxyl group or from an
intermediate or linking group, maybe an alkyl, substi-
tuted aryl, aryl, alkenyl, cycloalkyl or cycloalkenyl
group or even combinations of these functions such as
alkylary! or arylalkenyl, to name but two of the many
possible hydrophobic combinations. The hydrophobic
radical function characteristically has between 5 and 20
carbon atoms. When this hydrophobic radical function
comprises an alkyl or alkenyl group, this group may be
straight or branched. Polar functions such as hydroxyl
groups, for example, substituted on the hydrophobic
radicals would tend to lessen their hydrophobicity and
May render them less useful for the purposes of the
present invention.
In certain cases the R; and R2 functions maybe inter-
linked, for example when two acetate or propionate
functions are bound together by a nitrogen atom. In
these cases the Ri and R2 functionsare a single carbox-
ylato dianion. An alkyl] hydrophobic function having
between six and twenty carbon atoms, such as n-decane,
for example, may be boundtotheinterlinking nitrogen
and. the resultant compound utilized in the production
of the platinum (II) four coordinate complex of the
present invention.
With certain hydrophobic radical functions (cyclo-
pentene, for example) present on the carboxylato mo-
noanion it was found thatefficient incorporation of PT












on characteristics of the R3 function. For example,
when R3 was 1, 2 diaminocyclohexane (DACH)the
amino groups maybe in several relative stereochemical
configurations, cis, trans-RR and trans-SS (a mixture of
these being termed “racemic”). With platinum (II) com-
plexes containing cyclopentene radical functions (R1
and R2) and various stereochemical types of DACHit
was found that the trans-RR-DACH ‘and trans-SS-
DACH-complexes were more efficiently incorporated
into phospholipid liposomes (vesicles being a term
equivalent to liposomes) than were the analogous race-
mic DACH complexes.
When a hydrophobic radical function was a branched
alkyl containing nine carbon atoms such as that in.
neodecanoato, (C}oH29O2, empirical formula) the incor-
poration efficiency of a platinum (II) complex compris-
ing racemic DACHortrans-RR-DACH was maximal
(100%). Thus, linear or branchedalkyl radical functions
having from about 6 to about 12 carbon atoms confer
properties of efficient phospholipid liposome incorpora-
tion upon any DACH-containing Pt (II) complex.
Liposomes containing the platinum (II) complexes
described herein may be prepared from various am-
phipathic substances including natural or synthetic
phospholipids. The phospholipids usable to produce
liposomes are numerous and not exhaustively listed
herein since they are generally well knownin the art.
These phospholipids include but are not limited to:
lecithin, phosphatidylethanolamine, lysolecithin, lyso-
phatidylethanolamine, phosphatidylserine, _phos-
phatidylinositol, sphingomyelin, cardiolipin, phospha-
tidic acid and the cerebrosides. Most preferable phos-
pholipids for the practice of aspects of the present in-
vention include dimyristoylphosphatidylglycerol
(DMPG) and dimyristoylphosphatidylcholine
(DMPC). Cholesterol in minor proportions ranging
from less than 1% to about 50% maybe included with
phospholipids and platinum (II) complexes to produce
liposomesofthe present invention. A preferable but not
limiting combination of DMPG and DMPChas been
foundto bea ratio of 3 to 7 although ratios between 1:10
and 10:1 are contemplated as satisfactory. Ratios of
platinum (II) complex to phospholipid between about |
to 10 and about 1 to 30 are contemplated as generally
satisfactory although a 1 to 15 ratio was primarily used
in studies thus far.
Either unilamellar or multilamellar or other platinum
(II) complex—containing liposomes may be used in the
practice of the present invention. Multilamellar lipo-
somes are presently preferred since the platinum (11)
complexes of the present invention are substantially
water-insoluble and they appear to be incorporated into
the phospholipid bilayers of the liposome lamellae.
Generally, the procedure for synthesis of the plati-
num II compounds of the present invention may be
described on onescale as follows: (1) about 10 mmole
vicinal diamino cycloalkane or alkane are added to. 50
ml aqueous solution of K2Pt Cl, (3.5 g) and stirred for
six to eight hours at room temperature. The yellow
solid formed comprising cis-bis-dichloro-1,2-diamine-
Pt(IT) may be removed byfiltration and washed with
fluids such as water, methanol or acetone. The solid
may then be suspended in about 20 mi H2O and an
aqueoussolution containing about 0.75:g Ag2SO4 added
thereto. After stirring for about 24 hours in the dark,
precipitated Ag Cl may be removedbyfiltration. The
sulfato-vicinal diamine-Pt may then be dissolved in
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about 100 m! H2O and added to about 2 m molofalkali
earth metal salt of a carboxylato anion prepared in situ,
and stirred therewith for about 30 minutes. After re-
moval of BaSQO,byfiltration, the platinum IJ complex
of the present invention may be obtained, for example
by crystallization or removal of the solvent by evapora-
tion.
The methods of preparation of particular platinum
(II) complexes and chemotherapeutic treatment with
particular platinum (II) complexes described in the Ex-
amples contained later herein are readily adapted to the
production and use of analogously described and
claimed complexes by simple substitutions of appropri-
ate vicinal diamines or hydrophobic radical-containing
carboxylato monoanions.
Liposomes comprising phospholipids and platinum
complexes (Pt-liposomes) of the present invention are
useful in inhibiting both the growth and metastatic
spread of tumors.
Such Pt-liposomes may be administered parenterally,
topically or orally. Oral or parenteral dosages of these
Pt-liposomes between about 2.5 mg/kg body weight
and 25 mg/kg body weight are contemplated as ade-
quate in most conditions. The particular dosages, if a
tumor-bearing humanis being treated may vary in each
case according to the condition of the patient, the type
and extent of tumor, and particular Pt-liposome toxic-
ity.
The amount of liposomal-platinum included in the
pharmaceutical composition and the dosage utilized in
the method of treatment of the invention will vary de-
pending in each case upon the conditionsofthe patients,
the nature of the tumor undergoing treatment, antitu-
mor activity of liposomal-platinum, the toxicity and
solubility characteristics thereof, etc. Liposomal-
platinum may also be administered in combination with
other antitumor agents in a combined therapeutic regi-
men.
Parenteral administration may be intraperitoneal,
subcutaneous, intrapleural, intrathecal, intraurethral,
intravenous, intraarterial, intramuscular or intralym-
phatic. Such parenteral administration preferably in-
volves Pt-liposome suspensions in pharmaceutically
acceptable solutions such as sterile isotonic aqueous
solutions. These suspensions may be obtained fully pre-
pared or may be prepared from preformed components.
As knownto those skilled in the art, Pt-liposomes may
be prepared as pellets or powders. These pellets or
powders may be mixed with pharmaceutically accept-
able solutions to form suspensions for parenteral admin-
istration.
Topical administration of Pt-liposomes may involve
pharmaceutical compositions such as suspensions,
creams or ointments which may be obtained fully pre-
pared or prepared from Pt-liposome powdersorpellets.
Suchtopical administration may be nearto sites of can-
cerous lesions such as the epithelium or mucosa for
example.
Oral administrations of Pt-liposomes preferably in-
volve encapsulation of Pt-liposome powderor pellets
whereby the Pt-liposomes are protected from much
gastric and intestinal digestive activity before release
from the encapsulation.
When desired, Pt-liposomes may be prepared to con-
tain, for example, other therapeutic agents for treatment












Use of the complexesof the present invention, partic-
ularly as a component of liposomes, focuses upon the
inhibition of tumor growth and prevention of the meta-
static spread of tumors. For example, first a host is
identified as bearing a tumor type knownto generally
contain cells whose growth is often inhibited by plati-
num (II) complexes. Tumor growthin the host may be
inhibited by administering to the host the PT-containing
liposomesof the present invention.
Similarly, the metastatic spread of tumors in a host
may be inhibited. A host bearing metastatic or poten-
tially metastatic tumors of a type noted often to be
sensitive to platinum (ID complexes, would first be
identified. The administration of the PT-containing
liposomes of the present invention to that host would
serve to inhibit metastatic spread.
The following examplesare presented to furtherillus-
trate preferred embodiments of the present invention;
they are not intendedto limit the invention unless other-
wise so stated in the accompanying claims.
EXAMPLE1
Materials and Analyses
K2PtCly was purchased from AESAR (Johnson Mat-
they, Inc. Seabrook, N.H.). Cyclopentenecarboxylic
acid was purchased from Pfaltz and Bauer, Inc., Stam-
ford, Conn.; 1,2-diaminocyclohexane (DACH) from
Aldrich Chemical Co., Milwaukee, Wis., trans-RR-
DACH and trans-SS-DACH from Mortol Thiokol,
Inc., Danvers, Mo., and neodecanoic acid from Exxon
Chemical Co., Houston, Tex. Elemental analyses on the
platinum complexes were performedby Integral Micro-
analytical Laboratories, Inc., Raleigh, N.C. and by
Robertson Laboratory, Inc., Florham Park, N.J. Infra-
red spectra of the complexes (as KBr pellets) were mea-
sured in the range of 600-4000 cm—!using a Nicolet
6000 Fourier transform infrared spectrophotometer.
Chromatographically pure (thin-layer chromatogra-
phy) dimyristoylphosphatidylcholine (DMPC) and
dimyristoylphosphatidylglycerol (OMPG)used in this
study were obtained from Avanti Polar Lipids (Bir-
mingham, Ala.). Cholesterol was purchased from Sigma






platinum (IT) was onecis-platinum (CDDP) hydropho-
bic analogue used as a prototype to develop liposomal-
platinum (L-PT) preparations. The general structure of





This prototype was synthesized using a multi-step
procedure as described for racemic DACH (Khokharet
al. Inorg. Chem. Acta. Bioinorganic Section, V 108, p
63 (1985) follows: 0.96 g of DACH were added to a
filtered aqueoussolution of K2PtCl4 (3.5 g in 50 ml HzO
) and the mixture wasstirred for six to eight hours at
room temperature. The yellow solid containing cis-bis-
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dichloro-DACH-Pt (ID was removedbyfiltration and
washed with H20 , methanol, and finally acetone. After
the final product was dried under vacuum,the yield was
calculated to be 56%. Subsequently, 1.0 g of cis-bis-
dichloro-DACH-Pt (II) was suspended in 20 mi H20
and an aqueoussolution of Ag2SOxz (0.75 g in 150 ml
H20 ) was added to obtain water soluble sulfato-
DACH-Pt H20.Thereaction mixture was stirred in the
dark for 24 hours and the precipitated AgCl was re-
moved by filtration. The yellow solution was evapo-
rated to dryness at 45°-50° C under reduced pressure
and the yellow product was further dried over P2Osin
vacuum. The yield of sulfato-DACH-Pt (II) H2O was
90%.Finally, 0.423 g (1 mmol) of sulfato-DACH-Pt(II)
was dissolved in 100 ml of H2O ,and the barium cy-
clopentenecarboxylato was preparedin situ by the addi-
tion of 0.3 g of Ba(OH)2 to 0.226 g (2 mmol) of cy-
clopentenecarboxylic acid in H2O. These components
were mixed and the reaction mixture was stirred for 30
minutes at room temperature. The BaSO, precipitate
was filtered off, and the yellow filtrate was evaporated
to dryness at 45° C under reduced pressure using a
rotary evaporator. A yellow solid was obtained, which
was purified from methanol. The product was finally
dried under vacuum. Yield was 70%. Analysis: C
40.26%, H 5.65% and N 5.05% CigH30N204Pt (PT)
(theoretically C 40.67%, H 5.65% and N 5.27%. The
infrared spectrum for the complex (as KBr pellet)
/C=O 1632 cm—! and /C—O 1398 cm-!.
Cis-bis-cyclopentenecarboxylato-1,2-DACH-Pt (II)
is highly soluble in methanol and chloroform and only
slightly soluble in water (less than 0.5 mg/ml). The
above-described synthetic procedure was carried out
with both trans-RR-DACH and trans SS-DACH to
produce the trans-RR and trans-SS isomers ofcis-bis-
cyclopentenecarboxylato-1,2-DACH-Pt (II). The anal-
ysis of cis-bis-cyclopentenecarboxylato-1,2-trans-RR-
DACH-Pt (1D-3H20 was: C-37.36%, H-5.50%, N-




Sulfato-racemic-DACH-platinum (II) (0.423 g), pre-
pared as described in Example 2, was dissolved in 10 m1
water. A potassium salt of neodecanoic acid (0.420 g)
was added to this solution and the reaction mixture
stirred for 30 minutes at room temperature. A gummy
mass was obtained which was extracted in chloroform
and the chloroform extract was dried over anhydrous
MgSOxq. The MgSOg was separatedbyfiltration and the
filtrate evaporated to dryness. An off-white solid prod-
uct was obtained which was dried in vacuo and over
P20s. This final product was stored at 0° C.
The elemental analysis of the final product was: C-
48.30%; H-8.10% and N-3.92%. The calculated ele-
mental values for a compound ofthe empirical formula;
C26Hs2N204Pt.is: C-47.93%; H-8.00% and N-4.30%.
The structural formula of the cis-bis-neodecanoato-












where R,R’,R” can be: CH3, C2Hs or C3H7to give a
carboxylato radical function CjoHi902 (MW =172) as
empirical formula.
Cis,bis-neodecanoato-DACH-platinum (II) was
highly soluble in methanol and chloroform andinsolu-
ble in water.
The above described procedure was carried out with
trans-RR-DACH to produce the trans-RR isomer of
cis-bis-neodecanoato-DACH-Platinum (ID. The analy-
sis of cis-bis-neodecanoato-RR-DACH-Platinum (II)





Sulfato-DACH-platinum ADH20 (0.423 g), prepared
as described in Example 2, was dissolved in 10 ml of
H20. The sodium salt of n-decyliminodiacetic acid was
prepared in situ by the addition of NaOH (0.08 g) to
N-decyliminodiacetic acid (0.273 g) in 50 ml of water.
This aqueoussolution of sodium N-decyliminodiacetato
was added to the sulfato-DACH-platinum solution and
stirred for 30 minutes at room temperature. The result-
ing solution was evaporated to dryness on a rotary
evaporator at 40° C. under reduced pressure. The yel-
low solid thus obtained wasdissolved in methyl alcohol
and filtered through Celite. The yellow filtrate was
evaporated to dryness in a rotary evaporator under
reduced pressure. A yellowcrystalline product was






An elemental analysis of the product showed: C-
39.28; H-7.12% and N-6.68%. The theoretical composi-
tion for a compound of the empirical formula,
C20H39N304Pt.2H20 , was: C-38.95%; H-7.02% and
N-6.81%. The infrared spectrum for the complex (as
KBrpellet) “C—O 1580 cm~! and / C—O 1410 cm—!.
The structural formula of the  cis-bis-n-





where R=n-decyl or a longer straight or branched
chain alkyl radical.
Cis-bis-n-decyliminodiacetato-DACH-Platinum (II)
is highly soluble in methanol and chloroform andinsol-
uble in water. The above described synthetic procedure
was carried out with trans-RR-DACHto produce the
trans-RR isomer of cis-bis-n-decyliminodiacetato-
DACH-Pt (ID. The analysis of  cis-bis-n-
decyliminodiacetato-trans-RR-DACH-Pt II was: C-
38.60%, H-6.87%, N-6.82% (theoretically C-38.95%,
H-7.02%; N-6.81%).
The above described compound represents a struc-
ture where Rj and R2 of the earlier described general
structure are one and the same and the carboxylato
monoanionsare bound togetherbya linking atom bear-









Multilamellar lipid vesicles (MLV)or liposomes con-
taining incorporated platinum complexes (PT) of the
above descriptions were prepared as previously de-
scribed for other compounds (Lopez-Berestein et al
(4)(1984) Clin. Exp. Metastasis V 2 pp 127-137 and
Lopez-Berestein et al (1983) J Inf Dis V 147 pp
937-945). In brief, chloroform solutions of lipids (at the
desired molar ratio) and PT were mixed at a lipid-PT
ratio of 15:1 and the chloroform was evaporated in a
rotary evaporator (Buchi, Brinkmann Instruments,
Westbury, N.Y.). The dried lipid film obtained, contain-
ing PT, was then dispersed with an aqueoussolution
(0.9% NaCl in water) by vigorous handshaking. The
suspension was subsequently centrifuged at 30,000xg
for 45 minutes, the supernatant was discarded, and the
pellet containing PT was resuspended in 0.9% NaCi
solution.
MLVor liposomes containing platinum complexes
may also be prepared from a lyophilized powder con-
taining lipid and platinum compound. The lipid and
platinum compoundare dissolved in the hydrophobic
solvent tertiary butanol (M.P. 26° C.) at the ratios de-
scribed above. Thesolution is freeze-dried and a white
powder obtained. MLV containing the platinum com-
pound are formed upon the addition of 0.9% NaCL
solution in water to the lyophilized powder with mild
shaking by hand.
EXAMPLE6
Calculation of Encapsulation Efficiency (EE) and
Stability
Elemental platinum (Pt) was determined in the lipo-
some suspension and the pellet by x-ray fluorescence as
previously reported (Seifert et al (1979) Proc. Amer.
Ass'n. Cancer Res. V 20 p. 168) in the Department of
Analytical Chemistry, The University of Texas Medical
School at Houston, Tex. The amountof platinum com-
plex (PT) was determined in the supernatant by ultravi-
olet (UV) spectrophotometry using a wavelength of 224
nm. The EE wasinitially calculated with the two fol-
lowing formulas:
1. EE=Pr in pellet/total Pt in the initial liposome
suspension
2. EE=Total Pt initially added - Pt in supernatant-
/total Pt initially added
Since the results obtained by these two methods were
highly comparable and the second method only requires
PT determination by UV spectrophotometry, most EE
determinations were calculated with the second
method.
The stability of the different liposome-PT (L-PT)
preparations in 0.9% NaCl solution at 4° C., and 50%
human (AB) serum in 0.9% NaClsolution at 37° C. was
determined using the following formula:
% _EE at x hours
% EE at 0 hours 100
Stability at x hours = x
The EE values used in the stability determinations
were obtained by measuring PT in the supernatants by
UV spectrophotometry (0.9% NaCl solution) or x-ray
fluorescence (50% human AB serum). Thestability in
0.9% NaC} solution was determined up to 14 daysafter
the initial preparation. In addition, the L-PT prepara-











the morphology of the.vesicles. The stability in 50%
human AB serum wasdetermined up to 18 hours after
incubation. ;
Different cis-platinum analogues were encapsulated
in multilamellar vesicles composed of DMPC:DMPG
7:3. The encapsulation efficiency for Pt-cyclopen-
tenecarboxylato racemic-DACH was 66%. The encap-
sulation efficiency was significantly increased when the
pure trans RR DACHortrans-SS-DACHisomers were
used (88% and 90%, respectively). The encapsulation
efficiency for Pt-neodecanoato-racemic-DACH, Pt-
neodecanoato trans-RR-DACH, Pt-n-
decyliminodiacetato racemic DACH complexes are
presented in Table I, shown below.
TABLE1
ENCAPSULATION EFFICIENCY OF

















'Mean ofat least three experiments. Liposome composition: DMPC:DMPG 7:3
Analogous experiments (not shown) with DMPC
alone, DMPG alone, cholesterol alone, DMPC and
DPMG combined in other concentrations, with or
without cholesterol showed no better encapsulation
efficiency and, most frequently, a significantly de-
creased EE. :
EXAMPLE7
Stability of L-PT in Aqueous Milieu
Preparations were suspended in 0.9% saline and incu-
bated at 4° C. for 14 days. The liposome compositions
were observed by light microscopy and the amountof
free PT in the saline determined. Liposomes containing
PT and composed of DMPGas the only phospholipid
showedsignificant microscopically determined loss of
structure. Free PT- was determined and stability was
calculated as the percentage PT remaining in the lipo-
somes. The results of these measurements are presented
in Table 2 below.
 
TABLE 2
STABILITY OF L—PT IN SALINE L—-PT AT 14 DAYS!









'Liposome composition: DMPC:DMPG 7:3
As maybeseen in the above data, both the cyclopen-
tenecarboxylato trans-RR-DACH and the Pt-
neodecanoato-racemic-DACHexhibit greater stability




Toxicity Studies of L-PT
(Cyclopentenecarboxylato-racemic-DACH)
Toxicology studies were carried out in 6-8 weeks old
CD-1 Swiss mice weighing 22-25 gm and purchased
from The University of Texas Science Park (Bastrop,
TX). Free PT in suspension in hydroxypropylcellulose,
DMPG, DMPG-PT, DMPC:DMPG 7:3 and
DMPC:DMPG 7:3-PT were administered intraperito-
neally (ip) in volumes ranging between 0.1 and 0.3 ml.
DMPC:DMPG 7:3-PT was also administered intrave-
nously (iv) in one single injection or in 3 daily injec-
tions. The clinical behavior and the survival times were
monitored on a daily basis. The LDio, LDsp and LDoo
were calculated considering the deaths occurring up to
14 days. after injection.
PT in suspension in hydroxypropylcellulose, DMPG-
PT and DMPC:DMPG7:3-PT had a similar LDs9 dose
level when given in a single intraperitoneal (ip) injec-
tion (91 mg/kg, 86 mg/kg and 75 mg/kg respectively)
(Table 3). The amount of PT that would be encapsu-
lated at the LDso dose level of empty liposomes com-
posed of DMPG and DMPC:DMPG 7:3 was higher
(183 mg/kg and >304 mg/kgrespectively) The LDso
dose for DMPC:DMPG7:3-PT injected iv was similar
for the two schedulesused: single injection and daily x3
injections (82 mg/kg vs 96 mg/kg). Most deaths in both
the ip and iv toxicity studies occurred between day 5
and 10 after injection. The results of these studies are
presented in Table 3.
TABLE3
 
TOXICITY OF DIFFERENT L—PT PREPARATIONS
(CYCLOPENTENECARBOXYLATO-RACEMIC-DACH)
ADMINISTEREDIP AND IV
L—PT Route of LDjg LDs5o LDoo
Preparation Administration mg/kg mg/kg me/kg
Free PT ip x 1 61 91 125
DMPG-PT ip x 1 56 86 133
DMPC:DPMG 7:3-PT ip x 1 54 75 94
iv x1 _ 82 100
iv qd xX 3 63 86 107
DMPG* ip x} 158 183 228
DMPC:DMPG7:3* ip X 1 >304 >304 > 304
 
*Results expressedin mg/kg of PT that would be encapsulated at the LDjo, LDsg
and LDog dose levels of empty liposomes.
EXAMPLE9
Nephrotoxiciiy
Blood urea nitrogen (BUN) was determined in sam-
ples obtained from the retroorbital plexus of CD; Swiss
mice weighing 22-25 gm 96 hoursafter the ip injection
(single dose) of CDDP, PT cyclopentenecarboxylato
racemic DACHin hydroxypropylcellulose, DMPG-PT
or DMPC:DMPG7:3-PT at doses correspondingto the
previously determined LDso. All L-PT preparations
tested for toxicity were. prepared understerile condi-
tions on the same day of the experiments. There were
no significant BUN elevations after the ip administra-
tion of t he LDso dose of PT in suspension in hydroxy-
propylcellulose, DMPG-PT and DMPC:DMPG 7:3-
PT (BUN at 96 hours 34.4+9.6 mg %, 30.044.6 mg %
and 32.0+2.3 mg % respectively. The results are shown











ACUTE NEPHROTOXICITY OF CDDP,
FREE PT (CYCLOPENTENECARBOXYLATO-
RACEMIC-DACH)




ip Single Injection BUNat 96 hours!
Preparation (mg/kg) (mg %)
CDDP 17 78.3 + 8.0
Free PT 91 34.4 + 9.6
DMPG-PT 86 30.0 + 4.6
DMPC:DMPG7:3 75 32.0 + 2.3
‘Normal = 27.2 + mg %
EXAMPLE10
In Vitro Antitumor Activity of
Cyclopentenecarboxylato-Racemic-DACH-Pt Against
L1210 Ceils
L1210 leukemic cells were grown in a suspension
culture in McCoy’s 5A medium (Gibco Laboratories,
Grand Island, N.Y.) supplemented with 10% horse
serum, glutamine, streptomycin and penicillin at 37° C.,
95% relative humidity in a 5% CO? atmosphere. Four
ml of cell suspension were added to culture tubes and
the appropriate concentration of free PT or L-PT was
added (from 0.01 micro g/m! to 10 micro g/mlfinal
concentration). After 96 hours, the cell concentration of
control and experimental cultures were calculated with
a Coulter Counter (Coulter Electronics, Hialeah, Fla.)
and the percent inhibition calculated. The following
preparations were tested: free PT, DMPG,
DMPC:DMPG 7:3, DMPG-PT and DMPC:DMPG
7:3-PT. Results were expressed as the dose achieving a
50% growth inhibition (IDs) Results for empty lipo-
somes were expressed as the amount of PT that would
have been encapsulated at the IDs59 concentration.
The IDs0 for free cyclopentenecarboxylato-racemic
DACHwas1.3 micro g/ml (Table 5). Of the two L-PT
preparations tested, DMPG-PT wasslightly more ac-
tive than DMPC:DMPG 7:3-PT (mean IDsp of three
experiments; 0.7 and 1.6 micro g/ml respectively).
Empty liposomes composed of DMPGhad an IDs of
3.7 micro g/ml while the IDso for empty liposomes




AGAINST L1210 CELLS OF
FREE PT, L—PT AND EMPTY LIPOSOMES
(were PT is cyclopentenecarboxylate-racemic-DACH-PT)
IDs9 (micro g/ml)!
 
Preparation Exp. 1 Exp.2 Exp. 3 Mean
Free PT 1.3 _ — _
DMPG-PT 0.7 1.0 14 0.7
DMPG?2 3.0 3.0 5.0 3.7
DMPC:DMPG7:3-PT 1.9 2.0 0.9 1.6
DMPC:DMPG7:32 > 10.0 _ — ~
 
'CDDP IDs = 0.1 micro g/ml
Deg expressed as micro g/ml of PT that would be encapsulated at the IDs
concentration of empty liposomes.
EXAMPLE11
In Vivo Antitumor Activity of L-PT Against L1210
Mouse Leukemia where PT is
cyclopentenecarboxylato-racemic-DACH




DMPC:DMPG 7:3, and DMPC:DMPG 7:3-PT was
tested in an L.1210-BDF; mouse model (25). BDF; mice
were purchased from Charles River (Wilmington,
Mass.). Groups of 6-8 mice weighing 18-22 gm were
inoculated ip with 1 106 L1210 leukemia cells on day
0. L1210 cells were kept in DBA, mice were weekly
passages between the different experiments. All L-PT
preparations wereinjected ip in volumesof0.1 to 0.3 ml
24 hours after tumor inoculation. Two different sched-
16
mice of six) were seen in the groups treated with
CDDP, DMPG-PT and DMPC:DMPG7:3-PT (Table
6).
In the experiment using a multiple dose schedule, the
highest % T/C obtained was 253 for CDDP 7.5
mg/kg X3, 284 for free PT 12.5 mg/kg x3, 179 for
DMPG-PT6.25 mg/kg X3 and 403 for DMPC:DMPG
7:3-PT 12.5 mg/kg x3. Long-term survivors (1 of 6
mice) were only observed in the group treated with
ules of administration were used: a single injection on 10 DMPC:DMPG 7:3-PT (Table 7).
TABLE6
IN VIVO ANTITUMOR ACTIVITY AGAINST MOUSEL1210 LEUKEMIA
OF CDDP, FREE PT AND L—PT ADMINISTEREDIP (DAY1)
where PT is cyclopentenecarboxylato-racemic-DACH
 
% T/C
Group : (Number of Survivors on Day 30)
Number Preparation* Exp. 1) -Exp.22 Exp. 33
i CDDP 10 mg/kg 167 — 189 (1/6)
2 Free PT 25 mg/kg — — 168
3 12.5 mg/kg 173 136 179
4 DMPG-PT 25 mg/kg 100 _ -
5 12.5 mg/kg 160 209 (2/6) 158
6 . 625 mg/kg — ~ 138
7 3.12 mg/kg — — 163 (2/6)
8 DMPC:DMPG 7:3-PT 25 mg/kg 213 200 (1/6) 232 (1/6)
9 12.5 mg/kg 167 (1/6) — 189 (1/6)
10 6.25 mg/kg — _ 200
Imedian survival of control = 7.5 days
2‘median survival of control = 11 days
3median survival of control = 9 days
4All preparations were injected ip in 0.}-0.3 ml 24 hours after the ip inoculation of 1 x 10°L1210 cells.
day 1 or an injection on days 1, 5 and 9 (multiple). The
doses of CDDP used were the ones that had resulted in
a maximum antitumoractivity in previous experiments.
The doses of PT, DMPG-PT and DMPC:DMPG7:3-
PT used ranged from 3.125 mg/kg to 50 mg/kg (ap-
proximate LDjo). Clinical behavior and survival times
were monitored until all animals had died. Results were
expressed as % T/C (median survival time of treated
mice/median survival time of control mice x 100) and
number of long-term survivors. Mice living more than
30 days and more than 60 days were considered to be
long-term survivorsfor the single and multiple injection
schedule respectively. All L-PT preparations tested for
antitumor activity were prepared understerile condi-
tions on the same day of the experiment.In thefirst set
of experiments, the effect of a single ip dose of CDDP,
free PT, DMPG-PT and DMPC:DMPG7:3-PTin the
treatment of L1210 leukemia was tested. Mice treated
with free PT at doses of 12.5 mg/kg and 25 mg/kg had
a % T/C comparable to those treated with 10 mg/kg of
CDDP(162 vs 178, means of three experiments) (Table
6). DMPG-PTat doses of 12.5 mg/kg, 6.25 mg/kg and
3.125 mg/kg had an antitumoractivity comparable to
free PY and CDDP (mean % T/C=175 for 12.5
mg/kg; 158 for 6.25 mg/kg; and 163 for 3.125 mg/kg)
(Table 6). Doses of DMPG-PT of 25 mg/kg or more
were toxic for L1210 leukemia-bearing BDF; mice.
Mice treated with DMPC:DMPG7:3-PT at doses of 25
mg/kg, 12.5 mg/kg and 6.25 mg/kg had asimilar or
slightly higher T/C than those obtained with CDDP,
free PT and DMPG-PT (mean: % T/C=215 for 25
mg/kg; 178 for 12.5 mg/kg; and 200 for 6.25 mg/kg)
(Table 6). DMPC:DMPG7:3-PT at a dose of 50 mg/kg
was toxic for L1210 leukemia-bearing BDF) mice.
Empty liposomes composed of DMPG and
DMPC:DMPG7:3, at doses equivalent to the optimal
ones of loaded vesicles (L-PT) did not shown antitumor
activity (% T/C=105 for DMPG and 93 for









IN VIVO ANTITUMOR ACTIVITY AGAINST MOUSE
L1210 LEUKEMIA OF CDDP, FREE PT AND L—PT





Number Preparation! Dose on Day60)
1 CDDP 7.5 mg/kg X 3 2530
2 Free PT 25 mg/kg X 3 158
3 12.5 mg/kg X 3 284
4 6.25 mg/kg X 3 168
5 DMPG-PT 12.5 mg/kg X 3 105
6 6.25 mg/kg x 3 179
7 3.12 mg/kg X 3 168
8 1.56 mg/kg x 3) 115
9 DMPC:DMPG7:3-PT 12,5 mg/kg x 3 403 (1/6)
10 6.25 mg/kg xX 3 253
11 3.125 mg/kg X 3 210 (1/6)
 
‘all preparations were injected ip in volumes of 0.1 to 0.3 mi 24 hours, 5 days and
9 days after tumor inoculation
EXAMPLE12
In Vivo AntitumorActivity of Different L-PT Analogs
Against L-1210 Leukemia
The antitumoractivity against L-1210 murine leuke-
mia of the different L-PT analogs was assessed in an
L-1210-BDF, mouse model (tumor inoculation day 0,
treatment day 1, ip) as described earlier herein. Com-
pared with CDDP (% T/C=175), the L-PT analogues
showed equivalent or slightly higher anti-tumoractiv-
ity, with the exceptions of L-PT (cyclopentenecarbox-
ylato trans-SS-DACH=155 and N-decyliminodiaceto
racemic-DACH=150 and  N-decyliminodiacetato





ANTITUMOR EFFECT AGAINST 11210





mg/kg on days, 8, 12, 16) on day 30 after the intrave-
nous inoculation of 105 M5076 cells (mean number of
liver metastasest+SD =39 +21 for L-PT vs 114438
for cis-platinum (Table 9). L-PT-NEODECANOATO-
 
Dose* 5 RACEMIC-DACH (25 mg/kg on days 4, 8, 12) re-
Platinum Analog mg/kg % T/C? sulted in the complete inhibition of liver metastases of
PT-cyclopentenecarboxylato- 25 213 M5076 on day 45 after the inoculation of 104 M5076
racemic-DACH cells, while 4/6 animals treated with cis-platinum (7.5
PT-cyclopentenecarboxylato- 25 187 mg/kg on days 4, 8, 12) had 175 or more liver metasta-
PTreveloperenzcarboxylato- 25 iss 10 ses (Table 10).
trans-SS-DACH L-PT-NEODECANOATO-RACEMIC-DACH
PT-neodecanoato-racemic-DACH 50 187 was effective in the prophylaxis of liver metastases of
Precanoato-trans-RR-DACH DACH : to M5076 reticulosarcoma. L-PT-NEODECANOATO-
_ ecyliminodiacetato-racemic-, . - .
PT—N-decyliminodiacetato trans-RR-DACH 25 162 RACEMIC-DACH(37.5 mg/kg on day -1) resulted in
Cis-platinum (CDDP)5 10 175 ‘15 a five-fold decrease in the numberofliver metastases on
Liposome composition’ DMPC:DMPG 7.3 day 21. after the intravenous inoculation of Jo# M5076
2 cells (inoculation day 0) compared with cis-platinum
Medi ival of treated mi . i .Pega Sareea oF treatermice x 100 (10 mg/kgon day -1) and untreated animals (mean num
31 x 10611210 cells inoculated ip on day 0. ber of liver metastases+SD =52 +20 for L-PT,
spreatment: ipon day 1 ml 20 256+54 for cis-platinum, and 226221 for control)
HSSOlV: in ine, #mg/m! (Table 11).
TABLE9
Treatment of Liver Metastases of M5076 Reticulosarcoma
with L_PT-NEODECANOATO-RACEMIC-DACH.
Day 30 | Dose Schedule No. Liver Metastases on
Treatment mg/kg day mean + SD
Cis-platinum 7.5 8, 12, 16 114 + 38
L—PT-NEODECANOATO- 25 8, 12, 16 39 + 21
RACEMIC-DACH
EXAMPLE13
In Vivo Antitumor Activity of
L-PT-NEODECANOATO-RACEMIC-DACH
Against Liver Metastases of Mouse M5076
Reticulosarcoma
The potential antitumor effect of L-PT against liver 55
usingmetastases was tested
*Groupsof 10 C57BL/6 mice wereinoculated on day 0 with 10° M5076cells intravenously. Animals
were treated on days 8, 12, and 16 with cis-platinum or L—PT-NEODECANOATO-RACEMIC-
DACH.The median survival of untreated animals was 19 days. Treated animals weresacrificed on




Treatment of Liver Metastases of M5076 Reticulosarcoma
with L—PT-NEODECANOATO-RACEMIC-DACH
Day 45 Dose Schedule No. Liver Metastases on
Treatment mg/kg day mean + SD
Cis-platinum 7.5 24,812 0,0, 175, >200, >200, >200
L—PT-NEODECANOATO- 25
RACEMIC-DACH
*Groups of 6 C57BL/6 mice were inoculated on day 0 with 104 M5076cells intravenously. Animals
were treated on days 4, 8. and 12 with cis-platinum or L—PT-NEODECANOATO-RACEMIC-
DACH.The median survival of untreated animals was 30 days. Treated animals were sacrificed on day
45, the livers dissected, placed in Bouin's fixative, and the numberofliver-tumor colonies counted. Two
of the animals treated with cis-platinum died before day 45 versus none in the group treated with
L—-PT.
4, 8,12 0, 0, 0, 0, 0, 1
50
TABLE i1





described in Example 6 and t he mouse M5076reticulo-
sarcoma, whichis a tumor that metastasizes exclusively
to the liver.
L-PT-NEODECANOATO-RACEMIC-DACH
was more active than cis-platinum in the treatment of
established liver metastases of M5076 using twodiffer-
ent tumor inocula and schedules of administration
(Table 9 and 10). L-PT-NEODECANOATO-
RACEMIC-DACH(25 mg/kg on days, 8, 12, 16) re-
sulted in a more than two fold reduction in the number
of liver metastases compared with cis-platinum (7.5
No.Liver Met-
Day21 Dose Schedule astases on
60 Treatment mg/kg day mean + SD
None - _ 226 + 21
Cis-platinum 10 1 256 + 54
L—PT-NEODECANOATO- =37.5 1 52 + 20
65
RACEMIC-DACH
*Groups of 6 C57BL/6 mice were treated on day | with cis-platinum or L—-PT
Neodecanoato-Racemic-DACH.Animals were inoculated on day 0 with 10 M5076
cells intravenously. The median survival of untreated animals was 21 days. Treated
animals were sacrificed on day 21, the livers dissected, placed in Bouin's fixative,







Cis-diamine-diiodo-platinum (II) (NH3)2 Pt-I2 was 5
first prepared by the following method:
Kz PrtCl,4 (5 g) was dissolved in water (20 ml). An
aqueoussolution of KI (3 g) was added and a dark
brown solution was obtained. Aqueous concen-
trated ammonia (2 ml) was added to the mixture
which was stirred for 2-3 hr. at room temperature.
The mixture was filtered and the solid was washed
with an excess of water, ethanol and ether. The
product was dried over P2Os under vacuum.Yield
4.5 g (77%).
The compoundaccording to the invention was then
prepared as follows:
(NH3)2-Pt-I2 (1.0 g) was suspended in water (50 ml),
and aqueous solutions of AgNO3 (0.68 g 20 ml H20)
was added thereto. The reaction mixture was stirred
overnight at room temperature in the dark. The Agl
precipitate wasfiltered and filtrate was concentrated by
rotary evaporation. To the concentrated solution a solu-
tion of sodium neodecanoatopreparedin situ, (neodeca-
noic acid 0.688 g in 20 m! methanol and 1N NaOH,4
ml) was added. The reaction mixture wasstirred over-
night at room temperature. The yellow reaction mix-
ture was evaporated to dryness at 40° C. under reduced
pressure using a rotary evaporator. A gummy product
was obtained which was extracted in chloroform and
the chloroform extract was dried over anhydrous
MgSO4 MgSO«gwasseparated byfiltration and filtrate
was evaporated to dryness under reduced pressure
using a rotary evaporator. A cream-color solid was
obtained which was dried over P205in vacuo. Thefinal
product was stored at 0° C.
The elemental analysis of the final product was
C41.58, H8.03; N 4.45%. The calculated values for
C29H44N24Pt. is C42.00; H7.7, N4.90%.
The structural formula of the cis-bis-neodecanoato-
bis-diamine-platinum (ID),is as follows:
[H3N}—Pt—[OOC—CR'RR"}2
where R, R’, R’ can be CH3, C2 Hs or C3H7to give a
carboxylato radical function with C1oHi902
(MW =171) as empirical formula.
Cis-bis-neodecanoato-bis-diamine-platinum (II) is
highly soluble in chloroform, methanol and other com-




The method of Example 14 was followed, using the
cyclohexylamineligand in place of ammonia. The com-
plex is highly soluble in chloroform, methanol and other
organic solvents, but insoluble in water.
Elemental Analysis; Calculated for C32H64N204.2-
H2O, C49.71; H8.80, N3.62%, found C49.31; H8.39;
N3.16%
The structural formula of the cis-bis-neodecanoato-










where R, R’, R” can be CH3, C2Hs or C3H7to give a






Cis-diiodo-ethylenediamine-platinum (II), was first
prepared by the method of ExampleI, using ethylenedi-
amineligand in place of ammonia and with a 96% yield
of product.
Sulfato-ethylenediamine-platinum (II). HzO was pre-
pared by the following method.
Cis-bis-diiodo-ethylenediamine-platinum (ID, (3.9)
was suspended in 10 ml H2O and an aqueoussolutions
of Ag2SOg (2.2 g in 200 ml H2O) was added thereto.
The reaction mixture was stirred in the dark overnight
at room temperature. Ag] was removedbyfiltration
and the yellow filtrate was evaporated to dryness at
40°-45° C. under reduced pressure using rotary evapo-
ration. The final product was dried over P2Os5 under
vacuum. The product yield was 2.35 g (81%).
The compoundaccording to the invention was then
preparedas follows:
Sulfato-ethylenediamine-platinum (II), H2O (0.369 g)
wasdissolved in H2O (20 ml) and a solution of sodium
neodecanoato preparedin situ (neodecanoic acid, 0.344
g in 20 ml methanol and IN NaOH,2 ml) was added
thereto. The reaction mixture wasstirred for 2-3 hr. at
room temperature. The reaction mixture was evapo-
rated to dryness at 40°-45° C. under reduced pressure
using rotary evaporation. A gummy product was ob-
tained which wasextracted in chloroform and the chlo-
roform extract was dried over anhydrous MgSOg4. The
MgSOgwasseparated byfiltration and the filtrate was
evaporated to dryness under reduced pressure using a
rotary evaporator. The final product was dried over
P2Os in vacuo. The product was stored at 0° C.
Elemental analysis; calculated for C22H4sN2O04Pt.
H20, C42.86; H7.79; N 4.54%, found C43.07; H 7.32; N
4.71%.
Cis-bis-neodecanoato-ethylenediamine-platinum (I)
is highly soluble in chloroform, methanol and other
organic solvents, but insoluble in water.
The structural formula of the cis-bis-neodecanoato-




where R, R’, R” can be CH3, C2Hs or C3H7to give a






(I) and sulfato-bis-isopropylamineplatinum (II) were
first prepared by the method of Example 16, using iso-
propylamine ligand in place of ethylenediamine.




Sulfato-bis-isopropylamine-platinum (II). H2O (0.427
g) was dissolved in H2O (50 ml) and a solution of sodi-
um-neodecanoato prepared in situ (neodecanoic acid
0.344 g in 20 ml of methanol and 1N NaOH,2 ml) was
added thereto. The reaction mixture was stirred for 2-3
hr. at room temperature. The reaction mixture was
evaporated to dryness at 40°-45° C. under reduced
pressure using rotary evaporator. A gummy mass was
obtained which was extracted in chloroform and the
chloroform extract was dried over anhydrous MgSOx.
The MgSO«gwas separated by filtration andfiltrate was
evaporated to dryness under reduced pressure using a
rotary evaporator. The product was dried over P2Osin
vacuo. Thefinal product was stored at 0° C.
Elemental analysis, calculated for C26Hs6N2O4Pt,
C47.63; H8.53; N4.26%; found C 47.74; H8.47; N
3.93%.
The structural formula of the cis-bis-neodecanoato-
bis-isopropylamine-platinum (ID) is as follows:
({H3C}2CH—NH?)2—-Pt—_[OOC—C—R’RR"}2
where R, R’, R” can be CH3, CoHs or C3H7 to give a
carboxylato radical function with CioH1902
(MW= 171) as an empirical formula.
Cis-bis-neodecanoato-bis-isopropylamine-platinum
(ID,is highly soluble in chloroform, methanol and other






II H20 (0.423 g) was dissolved in H2O (20 ml) and a
solution of sodium-decanoato preparedin situ (0.344 g
decanoic acid in 20 ml methanol and IN NaOH 2 mi)
was added thereto. The reaction mixture wasstirred for
2-3 hr. at room temperature. The reaction mixture was
evaporated to dryness at 40°-45° C. under reduced
pressure using a rotary evaporator. A solid was ob-
tained which was extracted in chloroform and chloro-
form extract was dried over anhydrous MgSO,4. The
MgSO, was removedbyfiltration and filtrate was evap-
orated to dryness under reduced pressure using rotary
evaporator. The product was dried over P205 in vacuo.
The final product was stored at 0° C.
Elemental analysis—calculated for C26Hs2N204Pt.-
H20 C46.59; H8.06; N 4.18%, found C 45.94; H7.87 N
4.31%.
Cis-bis-decanoato-trans-R,R-1,2-diaminocyclohex-
ane-platinum II is highly soluble in chloroform and
other organic solvents, but insoluble in water.
The structural! formula of the cis-bis-decanoato-trans-
















Il. HzO (0.423 g) was dissolved in water (20 ml) and a
solution of barium-neopentanoato preparedin situ (neo-
pentanoic acid, 0.204 g, in 5 ml of methanol and Ba
(OH)2.8H20 0.3 g in 50 ml H2O combined together)
was added thereto. The reaction mixture was stirred for
2-3 hr. at room temperature. The reaction mixture was
evaporated to dryness at 40°-45° C. under reduced
pressure using a rotary evaporator. The residue was
extracted with methanol, filtered and the filtrate was
evaporated to dryness. A solid was obtained which was
further extracted with chloroform. The chloroform
extract was evaporated to dryness and a cream-color
product was obtained. The product was dried over
P20s under vacuum.
Elemental analysis calculated for CigH32N2O4Pt.2-
H20; C35.00; H6.57; N5.11%, found C35.16; H6.17;
N5.27%.
Cis-bis-Neopentanoato-trans-R,R-1,2-diaminocy-
clohexane-platinum II, is highly soluble in chloroform,
methanol and other commonorganic solvents.
The structural formula of the cis-bis-neopentanoato-







Encapsulation efficiency and antitumoractivity of
lipophilic cisplatin analogs
The compounds prepared in Examples 14-19 were
tested for their efficiency of encapulation in liposomes
by the methods described in Example 6. These lipo-
some-encapsulated compounds were tested to deter-
mine their optimal dose and effectiveness as inhibitors
of in vivo tumor growth as described in Example 12.
The data in Table 12 reveal the resultant measurements.
TABLE 12
 
Encapsulation Efficiency and Antitumor Activity of
Lipophilic Cisplatin Analogues Incorporated in Liposomes
Optimal % T/C
Encapsulation dose 11210 ip/ip
Compound Efficiency mg/kg single dose
Cis-bis-neodecanoato-cis-diamine-platinum (1H) 95% 50 200
Cis-bis-neodecanoato-bis-cyclohexylamine-platinum (II) 89% 100 125
Cis-bis-neodecanoato-ethylenediamine-platinum (II) 82% 75 144
Cis-bis-neodecanoato-bis-isopropylamine-platinum (II) 87% 100 150
Cis-bis-decanoato-trans-R,R-1,2-diaminocyclohexane-platinum (IJ) 96% 50 187





In Vitro cytotoxicity against human malignantcell lines HRs
5 H
Cis-bis-neodecanoato-1,2-diaminocyclohexane _plati-
num (II) wastested in the liposomal-form against three
human malignantcell lines of colon carcinoma (LoVo,
SW620, and SW403) using a colony formation inhibi-
tion assay. The drug concentration that resulted in a
50% inhibition of colony formation (C50) ranged from
4 to 8 uM. The ICSO ofcisplatinum for these same cell
lines ranged from 3 to 7 uM.
Changes may be made in the various compositions,
elements, steps and procedures described herein with-
out departure from the concept and scope of the inven-
tion as defined in the following claims.
Whatis claimedis:
1. A method of treating an animal afflicted with
tumorcells sensitive to a platinum (II) four-coordinate
complex, comprising administering to the animal a
pharmaceutically effective amountof a liposome which
comprises a phospholipid and a platinum (II) four-coor-





where R, and R2 are neo-decanoato of the formula
TOOCHEER
R"
where two of R, R’, and R”are methyl, ethyl, or pro-








wherein Rs is selected from the group consisting of
hydrogen, alkyl, aryl, aralkyl, alkenyl, cycloalkyl, or
cycloalkenyl having between | and 20 carbon atoms; or
wherein R3 and R4, when linked together, are se-
lected from the group consisting of cycloalkyl-1,2-
diamino having between about 3 and 7 carbon
atoms, and alkyl-vicinal-diamino having between
about 2 and 12 carbon atoms; and
said complex is defined further as being substantially
soluble in methanol or chloroform and substan-
tially insoluble in water.
2. The method of claim 1, where a plurality of the
liposomes are administered parenterally.
3. The method of claim’ 1, where the liposome is
administered by a method selected from the group con-
sisting of intravenous, intraarterial, intramuscular, in-
tralymphatic, intraperitoneal, subcutaneous, intrapleu-
ral, and intrathecal injection, topical application, and
oral dosage.
4. The method of claim 1, where the administration of
the liposome is repeated on a timed schedule.
5. The method of claim 1, where R; and R2are alkyl-
carboxylate having between about 5 and 20 carbon
atoms. ,
6. The method of claim 5, where R; and R2 are
branched chain alkylcarboxylate.
7. The method of claim 6, where R; and R2 are
branched chain alkylcarboxylate having n carbon




where twoof R, R’ and R”are each methy], ethyl, or
propyl, and the sum of the carbon atomsof R, R’, and
R” is n—2.
8. The method of claim 7, where n is 10.
9. The method of claim 7, where n is 5 and R, R’, and
R”are each methyl.
* * * mk Ok
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